This stromal-rich tumor subtype has similarities with the “p53-like” non-responding tumors not responding to upfront chemotherapy in the initial subtyping landmark paper [9], while the major impact of FGFR1 itself has not been reported in previous publications. Here, TP53 is linked to neoplasm.